Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs
February 06, 2015 at 04:15 AM EST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.